Search

Simple Summary: We explored whether specific factors, like inflammation indicators in the blood, could help predict treatment outcomes for locally advanced cervical cancer (LACC). LACC is generally treated with a combination of chemotherapy and radiation. We wanted to see if these factors could help physicians personalize treatments for better results. Our study involved looking at various aspects, including inflammation indices in the blood and various clinical treatment details, in LACC patients. While some factors, such as age and hemoglobin levels, seemed to predict outcomes, there was no clear connection between inflammation indicators in the blood and results. These findings challenge previous ideas and highlight the importance of considering multiple factors to predict the prognoses of LACC patients. Locally advanced cervical cancer (LACC) is treated with concurrent chemoradiation (CRT). Predictive models could improve the outcome through treatment personalization. Several factors influence prognosis in LACC, but the role of systemic inflammation indices (IIs) is unclear. This study aims to assess the correlation between IIs and prognosis in a large patient cohort considering several clinical data. We retrospectively analyzed pretreatment IIs (NLR, PLR, MLR, SII, LLR, COP-NLR, APRI, ALRI, SIRI, and ANRI) in 173 LACC patients. Patient, tumor, and treatment characteristics were also considered. Univariate and multivariate Cox's regressions were conducted to assess associations between IIs and clinical factors with local control (LC), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). Univariate analysis showed significant correlations between age, HB levels, tumor stage, FIGO stage, and CRT dose with survival outcomes. Specific pretreatment IIs (NLR, PLR, APRI, ANRI, and COP-NLR) demonstrated associations only with LC. The multivariate analysis confirmed Hb levels, CRT dose, and age as significant predictors of OS, while no II was correlated with any clinical outcome. The study findings contradict some prior research on IIs in LACC, emphasizing the need for comprehensive assessments of potential confounding variables. [ABSTRACT FROM AUTHOR]

Purpose: PERSEUS-IT (NCT02289924) was a prospective, observational, 2-year study evaluating the effectiveness and treatment patterns of intravitreal aflibercept (IVT-AFL) in patients with neovascular age-related macular degeneration (nAMD) in routine clinical practice in Italy. Methods: Treatment-naïve patients with nAMD receiving IVT-AFL per routine clinical practice were enrolled. The primary endpoint was mean change in visual acuity (VA; decimals) from baseline to month (M) 12 and M24. Outcomes were evaluated for the overall study population and independently for the 2 treatment cohorts: regular (3 initial monthly doses, ≥ 7 injections by M12, and ≥ 4 injections between M12 and M24) and irregular (any other pattern). Results: Of 813 patients enrolled, 709 were included in the full analysis set (FAS); VA assessments were available for 342 patients at M12 (FAS1Y, 140 regular and 202 irregular) and 233 patients at M24 (FAS2Y, 37 regular and 196 irregular). In the overall FAS, the mean ± SD change in VA from baseline to M12 and M24 was + 0.09 ± 0.24 and + 0.02 ± 0.25 decimals, and there was a statistically significant difference between the regular and irregular cohorts in both FAS1Y (p = 0.0034) and FAS2Y (p = 0.0222). Ocular treatment-emergent adverse events were reported in 4.1% (n = 33/810 [safety set]) of patients. Conclusion: In PERSEUS-IT, clinically relevant functional and anatomic improvements were observed within the first 12 months of IVT-AFL treatment in routine clinical practice in Italy in patients with treatment-naïve nAMD. These gains were generally maintained across the 2-year study. The safety profile of IVT-AFL was consistent with prior studies. Trial registration number: ClinicalTrials.gov Identifier: NCT02289924. Date of registration: November 13, 2014. [ABSTRACT FROM AUTHOR]

Background: Far Infrared Waves (FIW) with frequency range among few hundreds gigahertz (GHz) and few terahertz (THz) display some positive effects on neurological and musculoskeletal disorders. Aims and Objectives: Our retrospective observational study describes the benefits observed by the administration of an infrared-trapping and focusing plaster (FIT-PATCH) in patients affected by different musculoskeletal and neurological symptoms. Materials and Methods: 100 patients were retrospectively reviewed through the Second Opinion Medical Network. Each patient sticked a FIT-PATCH every 5 days for 1 month upon the skin in the painful/inflamed area. Quality of life (QOL) assessment was evaluated by the Short Form-36 (SF-36) health survey questionnaire before starting the treatment and after the fourth week and the Visual Analogue Scale (VAS) completed the pre-post treatment subjective pain record. Results: SF-36 showed significantly improvement of the pre-post treatment scores (P < 0.03), pain score (P < 0.02), general health score (P < 0.03) and in the emotional component scores (P < 0.03). The VAS pain score was either improved (P < 0.02) after plaster administration. No side effects or allergenic skin reactions were reported along the study. Conclusions: The FIT patches improved the symptoms probably through a mechanism involving the sebaceous/sweat glands system spreading the fit irradiating infrared THz waves energy, to the surrounding tissues with both a thermal and electromagnetic putative effect. The occlusive mechanism of the patch on the skin surface increasing the local thermic gradient cannot be adequately supposed to be therapeutically effective, because the FIT patch locally applied induces haemodynamic microvascular modification, not only locally but also remote. Thus, the intrinsic chemical properties of the FIT formulation absorbs and concentrates the endogenous infrared waves amplifying and reverberating them into the underlying tissues near and far, through low-Qfactor helical antennas of the sweat glands spreading the energy all over the body. Hence, the claim is that fit basically absorbs and concentrates the endogenous infrared waves into the affected districts and accelerates symptoms recovery. [ABSTRACT FROM AUTHOR]